Cergutuzumab-Anti-CEACAM5/CD66e therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153(Pre-made Cergutuzumab Amunaleukin biosimilar, Fusion Protein) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Cergutuzumab-Anti-CEACAM5/CD66e therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153(Pre-made Cergutuzumab Amunaleukin biosimilar, Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Cergutuzumab Amunaleukin biosimilar, Fusion Protein, Cergutuzumab-Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153 Pre-made [IN |
|---|---|
| INN Name | cergutuzumab amunaleukin |
| Target | CEACAM5 |
| Format | Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Roche,?F. Hoffmann-La?Roche Ltd. (Basel Switzerland) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CEACAM5 |
| Package |
